Conversely, at the time of treatment completion, numerous IFN-γ studies have supported its use for effectively monitoring anti-TB therapeutic efficacy, with some studies demonstrating a progressive decrease in serum IFN-γ level at therapeutic completion [43], [44], [45]. Here, IFNG is linked to tuberculosis.